DarioHealth Corp. (DRIO)

NASDAQ: DRIO · IEX Real-Time Price · USD
6.53
0.67 (11.43%)
At close: May 16, 2022 4:00 PM
6.70
0.17 (2.60%)
After-hours:May 16, 2022 7:44 PM EDT
Market Cap144.13M
Revenue (ttm)24.98M
Net Income (ttm)-79.62M
Shares Out22.07M
EPS (ttm)-4.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume455,845
Open5.80
Previous Close5.86
Day's Range5.74 - 6.74
52-Week Range4.11 - 23.80
Beta1.37
AnalystsBuy
Price Target18.58 (+184.5%)
Earnings DateMay 12, 2022

About DRIO

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-s...

IndustryHealth Care Equipment & Supplies
Founded2011
Employees200
Stock ExchangeNASDAQ
Ticker SymbolDRIO
Full Company Profile

Financial Performance

In 2021, DarioHealth's revenue was $20.51 million, an increase of 170.76% compared to the previous year's $7.58 million. Losses were -$76.76 million, 160.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for DRIO stock is "Buy." The 12-month stock price forecast is 18.58, which is an increase of 184.53% from the latest price.

Price Target
$18.58
(184.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DarioHealth Reports Record Quarterly Revenues in its 2022 First Quarter

Total Q1 revenue of $8.06 million increased 124% over the comparable prior year period and 34% sequentially over Q4 2021 Accelerated Business-to-Business (B2B) transformation with 14 new B2B accounts in...

4 days ago - PRNewsWire

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it's Q1 report. Some of it's shortfall was attributed by management to longer sales cycles in the insurer and employer space i...

5 days ago - Benzinga

DarioHealth to Report First Quarter 2022 Results on Thursday, May 12

Company to host conference call and webcast at 8:30 am ET NEW YORK , May 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announc...

1 week ago - PRNewsWire

DarioHealth Presents New Clinical Research Demonstrating Improved Outcomes for Participants Using a Single Integrated...

New research offers fresh evidence that a single digital therapeutics platform can improve outcomes for commonly co-occurring conditions NEW YORK , April 27, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasd...

2 weeks ago - PRNewsWire

DarioHealth Announces Agreement with Health Plan Colorado Access

New health plan partnership improves access to digital health for historically underserved populations NEW YORK, April 14, 2022  /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global ...

1 month ago - PRNewsWire

DarioHealth Announces Additional New Employer Contracts

NEW YORK, March 23, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new employer agreements: first, with a U.S. based...

1 month ago - PRNewsWire

DarioHealth Reports Fourth Quarter and Full Year 2021 Results and Operational Highlights

NEW YORK, March 22, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year...

1 month ago - PRNewsWire

DarioHealth to Report Fourth Quarter and Full Year 2021 Results on Monday, March 21

NEW YORK, March 14, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth...

2 months ago - PRNewsWire

DarioHealth Announces Two New Contracts within the Employer and Provider Market

NEW YORK , March 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new agreements with a regional employer and a regiona...

2 months ago - PRNewsWire

DarioHealth to Participate in the Cowen 42nd Annual Healthcare Conference

NEW YORK, March 7, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 42nd Ann...

2 months ago - PRNewsWire

DarioHealth Enters into Strategic Agreement with Sanofi U.S.

NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced it has entered into a strategic agreement with Sanofi U.S., ...

2 months ago - PRNewsWire

DarioHealth Announced Pricing of its Registered Direct Offering for Aggregate Proceeds of $40 Million Priced At-The-M...

NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive a...

2 months ago - PRNewsWire

DarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for ...

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstr...

3 months ago - PRNewsWire

DarioHealth Announces Four New Employer Contracts

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeuti...

3 months ago - PRNewsWire

DarioHealth Enters Agreement to Acquire Physimax, a Leading Provider of Validated Computer Vision for Musculoskeletal...

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market (the Company), announced it has entered into an agreement to purchase a...

3 months ago - PRNewsWire

DarioHealth Enters into Agreement with Large Regional Health Plan

NEW YORK, Jan. 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ-CM: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has contracted with a large regional health plan...

3 months ago - PRNewsWire

DarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022

NEW YORK, Jan. 18, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the...

3 months ago - PRNewsWire

DarioHealth Announces Two New Contracts within the Employer Market

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized di...

4 months ago - PRNewsWire

DarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits...

4 months ago - PRNewsWire

DarioHealth Announces Two New Contracts within the Employer and Provider Markets

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced new contracts today to provide its highly personalized digita...

5 months ago - PRNewsWire

DarioHealth Announces Two New Employer Contracts

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two employers to provide i...

5 months ago - PRNewsWire

Recap: DarioHealth Q3 Earnings

DarioHealth (NASDAQ:DRIO) reported its Q3 earnings results on Monday, November 15, 2021 at 04:30 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

DarioHealth Reports Third Quarter 2021 Results and Operational Highlights

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter of 2021 and provided...

6 months ago - PRNewsWire

DarioHealth Appoints Seasoned Health Care Executive Jerrod Helms as Chief Commercial Officer

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly create...

6 months ago - PRNewsWire

DarioHealth Earnings Preview

DarioHealth (NASDAQ:DRIO) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

6 months ago - Benzinga